BRCA1突变携带者35岁行PGT-M联合降低风险手术比40岁更有效
该成本效果分析采用Markov模型,比较BRCA1突变携带者在35岁行IVF联合PGT-M后立即行双侧输卵管卵巢切除术与延迟至40岁干预的成本效果。结果显示35岁策略绝对占优,每万名患者增加950例活产、减少726例卵巢癌和705例卵巢癌死亡,且成本更低、质量调整生命年更多。
要点
- BRCA1突变携带者35岁行IVF-PGT-M联合降低风险手术绝对占优。
- 每万名患者35岁干预增加950例活产,减少726例卵巢癌。
- 40岁干预每万名患者增加成本$3,721,823,减少24,379个QALY。
核心结论
- 模型提示BRCA1突变携带者35岁行IVF联合PGT-M较40岁更具成本效果,活产增加且卵巢癌减少。
- 尽管模型可辅助咨询,BRCA1突变携带者应与多学科团队共同决策。
研究设计与样本
- 成本效果分析,采用Markov数学模型。
- 概率、成本数据和效用值来自文献,用于估算两种策略的增量成本效果比。
主要发现
- 35岁行IVF-PGT-M后立即行双侧输卵管卵巢切除术对延迟至40岁绝对占优,增量成本效果比为-153(支付意愿阈值$100,000/QALY)。
- 每10,000名BRCA1突变携带者,35岁干预增加950例活产、减少726例卵巢癌和705例卵巢癌死亡。
- 40岁干预增加成本$3,721,823,并减少24,379个质量调整生命年。
- 概率敏感性分析显示35岁队列在所有支付意愿阈值下绝对占优,模型模拟至$200,000。
关键数值与推荐
- 支付意愿阈值设为每质量调整生命年$100,000。
- 增量成本效果比计算为-153。
- 每10,000名BRCA1突变携带者:35岁干预增加950例活产、减少726例卵巢癌、减少705例卵巢癌死亡。
- 40岁干预增加成本$3,721,823,减少24,379个QALY。
临床怎么用
- 可为BRCA1突变携带者咨询35岁行IVF-PGT-M联合降低风险手术的成本效果优势。
- 决策应结合多学科团队进行共享决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the cost-effectiveness of in vitro fertilization (IVF) with preimplantation genetic testing for monogenic disorders (PGT-M) at age 35, followed by risk-reducing bilateral salpingo-oophorectomy, to delaying interventions to age 40 among BRCA1 (BReast CAncer gene 1) mutation carriers. DESIGN: A cost-effectiveness analysis using a Markov mathematical model. SUBJECTS: Probabilities, cost data, and utilities were derived from the literature to estimate the incremental cost-effectiveness ratios between the two strategies. EXPOSURE: Age of interventions: age 35 or age 40. MAIN OUTCOMES MEASURES: Cost-effectiveness was the primary outcome, expressed as the ratio of differences in costs to the difference in quality-adjusted life years, and the willingness-to-pay threshold was set to $100,000 per quality-adjusted life year gained or lost. RESULTS: In vitro fertilization with PGT-M at age 35 followed by immediate bilateral salpingo-oophorectomy demonstrated absolute dominance over treatment delay until 40, with an incremental cost-effectiveness ratio between the two strategies calculated as -153 when using a willingness-to-pay threshold of $100,000. Per 10,000 patients with BRCA1, interventions at age 35 are associated with an additional 950 live births, 726 fewer ovarian cancer cases, and 705 fewer ovarian cancer deaths. Interventions at age 40 increased costs by $3,721,823 and resulted in 24,379 fewer quality-adjusted life years. Probabilistic sensitivity analysis revealed absolute dominance for the age 35 cohort at all willingness-to-pay thresholds, modeled up to $200,000. CONCLUSIONS: Our model suggests that performing IVF with PGT-M is cost-effective at age 35 compared with age 40 in BRCA1 mutation carriers, with an increased number of live births and decreased ovarian cancer cases. Although this model informs counseling, shared decision-making should be undertaken with a multidisciplinary healthcare team for BRCA1 mutation carriers.
引用
- Hunkler K, Boedeker D, Bulles K, et al. Preimplantation genetic testing for BReast CAncer gene 1 and risk-reducing surgery is more effective at age 35 than age 40. Fertil Steril. 2026. PMID: 41724460. doi:10.1016/j.fertnstert.2026.02.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。